back to home feed

NOVO NORDISK: UK'S NICE RECOMMENDS WEGOVY 2.4MG TO REDUCE MAJOR CARDIOVASCULAR EVENT RISK IN ADULTS WITH ESTABLISHED CVD & OBESITY/OVERWEIGHT; FINAL GUIDANCE EXPECTED BY END-APRIL; TO BE INTRODUCED WITHIN EXISTING NHS CARDIOVASCULAR CARE PATHWAYS